Navigation Links
Experimental Drug Helps Fight Aggressive Breast Cancer: Report

By Amanda Gardner
HealthDay Reporter

WEDNESDAY, Jan. 5 (HealthDay News) -- Researchers have taken another step in the hunt to find a treatment for an aggressive, likely-to-recur form of breast cancer.

In a study published in the Jan. 5 online edition of the New England Journal of Medicine, the experimental drug iniparib not only shrank tumors and increased the time they took to progress, but also surprised researchers by prolonging survival in women with what's known as triple-negative breast cancer.

This type of breast cancer lacks receptors for estrogen and progesterone and doesn't have large quantities of HER-2/neu protein, which the most successful cancer therapies target. This means that many currently available drugs simply won't affect it.

"We were surprised [at the results] because triple-negative breast cancer is very difficult to treat," said study lead author Dr. Joyce O'Shaughnessy.

"The big, big surprise was survival," added O'Shaughnessy, who nevertheless stressed that the trial was small and preliminary.

The findings were enough to generate the interest of Dr. Lisa A. Carey, the co-author of an accompanying editorial.

"It is early, but it's really exciting because it's a new class of drugs. It isn't that often that we have a completely new approach to treating cancer," said Carey, medical director of the University of North Carolina Breast Center in Chapel Hill. "This is a new book. We've just opened it up."

Iniparib inhibits a pathway that helps repair DNA; researchers call it the poly(ADP-ribose) polymerase (PARP) pathway. If this chain is interrupted, cancer cells don't have the necessary tools to repair themselves.

"[PARP inhibitors] work by preventing the cells from repairing damage to their DNA," Carey explained.

A similar drug, in fact, has shown benefit in patients with BRCA 1 or BRCA 2 mutations predisposing them to breast and ovarian cancer.

In this study, 123 patients with triple-negative breast cancer were randomized to receive a commonly used, well-tolerated chemotherapy regimen (gemcitabine and carboplatin) or to receive chemo plus iniparib.

More than one-half of the women responded to the combination treatment (meaning the tumor volume decreased) versus only about one-third of those receiving chemo alone.

Women receiving iniparib plus chemo lived an average of 12.3 months compared to just 7.7 months in the chemo-alone group. This may not seen like very long in either group, but for this serious a cancer, it is impressive, the researchers noted.

This was a phase 2 trial. O'Shaughnessy, who is co-director of breast cancer research at Baylor-Sammons Cancer Center, US Oncology, and Texas Oncology in Dallas, said the results of a larger (about 500 patients) phase 3 trial should be available within one to three months.

"The whole field is still preliminary and we have to be careful not to overhype the results [as] we're waiting on the results of the phase 3 trial," she said. "Phase 2 was quite positive, but we really don't know if this is going to end up benefiting patients until we get to phase 3."

In her editorial accompanying the study, Carey agreed. "Both excitement and caution are appropriate in interpreting the trial," she wrote. "Some clear drawbacks should be noted." Among them, she said, were the small size of the study group, "imbalances at baseline" favoring the iniparib group, and the "unconventional" chemotherapy regimen. But caveats notwithstanding, she concluded, the results may herald improved therapy "for an underserved subgroup of patients with breast cancer."

O'Shaughnessy added that the drug was "extremely well tolerated [by patients]. It didn't seem to add any appreciable toxicity to chemotherapy."

In the meantime, she pointed out, a woman walking through a clinic door who is diagnosed with triple-negative breast cancer shouldn't panic. "If it's only in the breast or lymph nodes, we cure most triple-negative cancers. But when it recurs and becomes metastatic, it's very difficult to treat," she explained.

The study was funded by BiPar Sciences, a subsidiary of Sanofi-Aventis which makes the drug.

More information

The U.S. National Cancer Institute has more on breast cancer.

SOURCES: Joyce O'Shaughnessy, M.D., co-director, breast cancer research, Baylor-Sammons Cancer Center, US Oncology, and Texas Oncology, Dallas; Lisa A. Carey, M.D., medical director, University of North Carolina Breast Center, Chapel Hill; Jan. 5, 2011 New England Journal of Medicine, online

Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Experimental Drug Offers Hope for Cystic Fibrosis Patients
2. Experimental Vaccine Shields Monkeys Against Ebola
3. Experimental targeted therapy shows early promise against medulloblastomas
4. Experimental nonsteroidal treatment of asthma shows promise
5. Experimental obesity drug avoids brain effects that troubled predecessors
6. Experimental treatments for cocaine addiction may prevent relapse
7. Experimental TB Test Called Fast and Accurate
8. Experimental Drug Shows Promise for Bone Marrow Disorder
9. Experimental Leukemia Drug Proves a Slam Dunk
10. Experimental Test May Spot Prostate Cancer Earlier, More Accurately
11. Experimental Drug Aids Kids With Nervous System Tumor
Post Your Comments:
Related Image:
Experimental Drug Helps Fight Aggressive Breast Cancer: Report
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, a Media ... give their videos a whole new perspective by using the title layers in ... Studios. , ProSlice Levels contains over 30 Different presets to choose from. ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the ... AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in ... topics including advance care planning, healthcare costs and patient and family engagement. , ...
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding emergency ... its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. Ogunleye ... M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. Ogunleye ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from reveals ...
(Date:6/24/2016)... ... ... was in a crisis. Her son James, eight, was out of control. Prone to extreme ... “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was ... other children and say he was going to kill them. If we were driving ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 2016  Consumers have taken a more active ... more emphasis on patient outcomes. ... the pharmaceutical industry have evolved beyond just providing ... are focusing on becoming more patient-oriented across their ... services that improve health. ...
(Date:6/24/2016)... , June 24, 2016  Global Blood ... biopharmaceutical company developing novel therapeutics for the treatment ... today announced the closing of its previously announced ... stock, at the public offering price of $18.75 ... offering were offered by GBT. GBT estimates net ...
(Date:6/24/2016)... June 24, 2016 ... announced the addition of the " Global Markets ... This report focuses ... an updated review, including its applications in various applications. ... market, which includes three main industries: pharmaceutical and biotechnology, ...
Breaking Medicine Technology: